Company press releases

Displaying 101 - 109 of 109 results
Released Company Title Industry Topic
22 Mar 2022
07:00 CET 		ARGENX SE argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis 20103010 Biotechnology Other subject
03 Mar 2022
07:00 CET 		ARGENX SE argenx Reports Full Year 2021 Financial Results and Provides Fourth Quarter Business Update 20103010 Biotechnology Other subject
28 Feb 2022
07:00 CET 		ARGENX SE argenx to Present at the 42nd Annual Cowen Health Care Conference 20103010 Biotechnology Other subject
24 Feb 2022
07:00 CET 		ARGENX SE argenx to Report Full Year 2021 Financial Results and Fourth Quarter Business Update on March 3, 2022 20103010 Biotechnology Other subject
10 Feb 2022
07:00 CET 		ARGENX SE argenx to Present at the 11th Annual SVB Leerink Global Healthcare Conference 20103010 Biotechnology Other subject
20 Jan 2022
08:00 CET 		ARGENX SE argenx Announces VYVGART™ Approval in Japan for the Treatment of Generalized Myasthenia Gravis 20103010 Biotechnology New
07 Jan 2022
07:00 CET 		ARGENX SE argenx Highlights Strategic Priorities for 2022 20103010 Biotechnology New establishment
03 Jan 2022
07:00 CET 		ARGENX SE argenx to Present at 40th Annual J.P. Morgan Healthcare Conference 20103010 Biotechnology Other subject
17 Dec 2021
23:09 CET 		ARGENX SE argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis 20103010 Biotechnology Meetings / events